4D Molecular Valuation
| FDMT Stock | USD 9.29 0.20 2.11% |
At this time, the firm appears to be overvalued. 4D Molecular Therapeutics owns a latest Real Value of $7.86 per share. The recent price of the firm is $9.29. Our model approximates the value of 4D Molecular Therapeutics from evaluating the firm fundamentals such as Shares Owned By Institutions of 81.18 %, return on asset of -0.28, and Shares Owned By Insiders of 3.61 % as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that 4D Molecular's price fluctuation is moderately volatile at this time. Calculation of the real value of 4D Molecular Therapeutics is based on 3 months time horizon. Increasing 4D Molecular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
4D Molecular's intrinsic value may or may not be the same as its current market price of 9.29, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.29 | Real 7.86 | Hype 9.29 | Naive 9.09 |
The intrinsic value of 4D Molecular's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence 4D Molecular's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of 4D Molecular Therapeutics helps investors to forecast how FDMT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 4D Molecular more accurately as focusing exclusively on 4D Molecular's fundamentals will not take into account other important factors: About 4D Molecular Valuation
The stock valuation mechanism determines 4D Molecular's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of 4D Molecular Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of 4D Molecular. We calculate exposure to 4D Molecular's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of 4D Molecular's related companies.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. The company was founded in 2013 and is headquartered in Emeryville, California. 4D Molecular operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 138 people.
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.